Back to search
Carbapenem-Resistant Enterobacteriaceae Colonization
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Carbapenem-Resistant Enterobacteriaceae Colonization trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Carbapenem-Resistant Enterobacteriaceae Colonization trials you may qualify forThe purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant…
Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly identified in children in China. Pediatric intensive care unit (PICU) is the high-risk area. Howe…
Carbapenem resistant Enterobacteriaceae (CRE) colonization of patients discharged from hospitals is a source of transmission to the community. In a cluster rand…
Antibiotic resistance (AR) is a critical public health threat and one of the greatest challenges of the 21st century. In an estimate of 2019, nearly 700.000 inf…
The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization peri…
A clinical study to eliminate intestinal colonization in subjects harboring microorganisms resistant to carbapenem and vancomycin antibiotics, thereby treating…
The goals of this observational study are to identify risk factors for ESBL-producing Enterobacterales and carbapenemase-producing Enterobacterales (CPE) coloni…
The aim of the study is to see whether fecal microbiota transplantation is effective to decolonize multidrug-resistant organisms.